Indonesian Political, Business & Finance News

Two in Five People with Cardiovascular Disease Face Higher Heart Attack and Stroke Risk Due to Inflammation

| | Source: Media Indonesia Translated from Indonesian | Health
Two in Five People with Cardiovascular Disease Face Higher Heart Attack and Stroke Risk Due to Inflammation
Image: Media Indonesia

Novo Nordisk has presented the latest findings from its global real-world evidence study, POSEIDON, at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece. The study revealed a crucial fact: cardiovascular inflammation remains highly prevalent in people with cardiovascular disease, even when they have received therapy in line with current standards of care.

Cardiovascular inflammation is inflammation of the blood vessels that often presents no symptoms (asymptomatic). Unlike an ordinary infection, if this condition persists over the long term it can significantly increase the risk of heart attack and stroke.

Data from the POSEIDON study show that two out of five people with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) experience cardiovascular inflammation. A similar condition was also found in two out of five heart failure patients across the ejection fraction spectrum.

In the study, inflammation was measured through high-sensitivity C-reactive protein (hsCRP) levels of ≥2 mg/L, a blood test commonly used to detect inflammatory risk in the vascular system.

These findings highlight a significant gap in current medical management. Even when patients have controlled their cholesterol, blood pressure and blood sugar in accordance with guidelines, cardiovascular risk driven by inflammation continues to lurk.

In Indonesia, the urgency of addressing this is very high, given that cardiovascular diseases such as stroke and ischaemic heart disease account for 30% of total national deaths, according to data from the Indonesian Ministry of Health. This challenge requires a more comprehensive and sustained approach to prevention and management.

Filip Knop, Senior Vice President and Chief Medical Officer of Novo Nordisk, stressed that understanding the extent of inflammatory risk is essential for developing innovative therapies in the future.

“The POSEIDON study provides important evidence that cardiovascular inflammation is a significant source of risk that persists even when patients have received standard therapy,” he said.

Inflammation plays a major role in the development of ASCVD and contributes to the progression of chronic kidney disease. Conversely, CKD can also trigger inflammation, creating a dangerous cycle of heightened cardiovascular risk. The condition is also commonly found in heart failure patients with obesity or metabolic disorders.

Professor Carolyn S.P. Lam of the National Heart Centre Singapore added that these findings change the medical perspective on residual cardiovascular risk.

“Inflammation is not a secondary issue, but a primary factor driving risk in millions of patients. This points to an opportunity for anti-inflammatory therapies currently under development to address unmet medical needs,” she explained.

Various international clinical guidelines from the ESC, AHA and ACC have now begun to incorporate hsCRP as an important biomarker for refining risk assessment and determining more intensive prevention strategies for high-risk patients.

More from 21 July 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/two-in-five-people-with-cardiovascular-disease-face-higher-heart-attack-and-stroke-risk-due-to-inflammation-1784609435)
Originally published by Media Indonesia (https://mediaindonesia.com/humaniora/912956/2-dari-5-orang-dengan-penyakit-kardiovaskular-memiliki-risiko-serangan-jantung-dan-stroke-yang-lebih-tinggi-karena-inflamasi), translated from Indonesian
Print